Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pre-emption After Supreme Court Ruling May Depend On How FDA Weighs Risk

Executive Summary

While the Supreme Court's landmark ruling in Wyeth v. Levine dashes pharmaceutical industry hopes for broad protection from product liability lawsuits, it will not trigger any sea change in litigation. Instead, the opinion seems likely to maintain the status quo and restrict the situations in which companies can claim they provided adequate warning of a drug's risks
Advertisement

Related Content

Industry Seeks Power To Trigger Safety Labeling Changes Under FDAAA
EHRs Have Potential To Help Manufacturers In Product Liability Cases – Former Pfizer General Counsel
High Court’s Vaccines Ruling Gives Drug Makers Hope For Design Defect Claim Pre-emption
Should Vaccine Makers Ever Be Liable For Design Defects? Supreme Court Amicus Briefs Argue Question
Wyeth Lawyer On Lessons Of Levine v. Wyeth: Look For Patterns of Risk, Actively Manage The Labeling
Pharma Outside the Fray As Obama Re-Evaluates Bush’s Pre-emption Policy
Pre-emption: Obama Administration Creeps Towards Reversing FDA Stance
Drug Safety Diligence Demands Proactive, Ongoing Assessment – FDLI Panel
Pre-emption Defense: Pharma Must Show Record Of Interaction With FDA
Roche Gets Second Chance In Accutane Liability Suit; Pre-emption Still Possible

Topics

Advertisement
UsernamePublicRestriction

Register

PS050792

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel